Please login to the form below

systemic lupus erythematosus

This page shows the latest systemic lupus erythematosus news and features for those working in and with pharma, biotech and healthcare.

Biogen scores mid-stage trial win for lupus drug BIIB059

Last approved treatment for Lupus was GSK's Benlysta in 2011. Biogen’s experimental drug for systemic lupus erythematosus (SLE) has hit the mark in a phase 2 trial, adding to ... BIIB059 hit all its objectives in the LILAC study, including a

Latest news

Second TULIP trial resurrects AZ’s lupus drug anifrolumab

Will now decide whether to file treatment for approval. A year ago, prospects for AstraZeneca’s systemic lupus erythematosus treatment anifrolumab were being written off. ... Lupus is a disease in which the immune system attacks normal cells and tissues
New data backs Merck’s segue into MS with BTK inhibitor

That mechanism also forms the basis of Merck’s testing of evobrutinib in rheumatoid arthritis and systemic lupus erythematosus (SLE), also at the phase 2 stage.
BMS psoriasis drug hits the mark in phase II

BMS also has phase II studies of the drug ongoing in other indications including systemic lupus erythematosus and Crohn's disease.
AstraZeneca’s Lupus treatment misses mark in trial

lupus erythematosus (SLE). ... control. The result of this trial is disappointing for patients and the lupus community.”.
Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

Ablynx also has vobarilizumab for systemic lupus erythematosus in phase II, with results due in the first half of the year that will trigger an option decision by AbbVie.

More from news
Approximately 2 fully matching, plus 23 partially matching documents found.

Latest Intelligence

Rethinking trials: the pros and cons of protocol amendments

A protocol change can work wonders – just ask AstraZeneca. In August, AstraZeneca’s systemic lupus erythematosus candidate anifrolumab achieved the primary efficacy endpoint in an amended trial called Tulip-2. ... Systemic lupus erythematosus is a
Pharma deals during September 2012

In a similar vein, Biogen Idec has sold its royalty rights to Benlysta (belimunab) for the treatment of systemic lupus erythematosus, to DRI Capital Managed Fund. ... Royalty monetisation. Benlysta (belimunab) for the treatment of systemic lupus

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Santhera CEO Klaus Schollmeier joins SuppreMol

This product is SM101, which is being investigated for its use in the treatment of primary immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Vice President: Competitive Salary Offered

Principal Medical Writer: £48 - 58, 000 according to skills and experience benefits

Director of Scientific Services, Medical Communications, Six fig...: Six figure salary

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Senior Medical Writer, MedComms Agency: Salary TBC

Account Manager– Medical Communications: (Negotiable - depending on experience)

Account Director or Senior Account Director: Salary TBC

Consultant: competitive salary

Subscribe to our email news alerts

PMHub

Add my company

Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

How do companies prepare for reimbursement?: Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
Integrating electronic health records into clinical trials: How organisations are working to realise the research potential of EHRs...
Keeping up the fight against HIV and using the lessons to tackle other threats: Danny Buckland interviews Gilead’s Mike Elliott...